Ruxolitinib, a Janus kinase inhibitor with selectivity for the JAK1 and JAK2 subtypes of this enzyme, was approved in 2011 by the FDA for the treatment of patients with myelofibrosis and polycythemia vera, has now also received marketing authorization from the European Commission for the treatment of nonsegmental vitiligo.

Chemelectiva has developed a new efficient continuous-flow process for the synthesis of Ruxolitinib, for which a patent has been filed.